Ariadne.ai secured €518,000 to develop TumorTwin, a 3D spatial-multiomics virtual tumor model intended to simulate glioblastoma behavior and predict responses to single and combination therapies. The company plans a prototype within a year and aims to integrate data from multiple spatial biology platforms to support research and, eventually, clinical decisions. In related science, a study using spatial single‑cell multiomics uncovered peripheral immune dysfunction patterns in Parkinson’s disease and inflammatory bowel disease, highlighting how coordinated tissue-level profiling can reveal clinically relevant immune alterations. Both developments underscore growing industry investment in spatial multiomics as a tool for therapy discovery and patient stratification.